MIRMMirum Pharmaceuticals, Inc. Common Stock

CSNasdaq (XNAS)·USD

Identity

Security key: 18577
Ticker: MIRM
Type: CS — Common Stock
Exchange: Nasdaq(XNAS)
Venue group: NASDAQ
Operating MIC: XNAS
Market: stocks
Locale: us
Currency: USD
Listed: 2019-07-18
Round lot: 100
Active: Yes
Last seen in a load: 2026-08-14 20:49
Vendor updated: 2026-08-13 06:09
Ticker root / suffix: MIRM

Detail

Enriched 2026-08-14 20:47

Market cap: $6,035,312,036.19
Shares outstanding (class): 64,932,203
Shares outstanding (weighted): 60,981,227
SIC: 2834 PHARMACEUTICAL PREPARATIONS
Employees: 418
Location: FOSTER CITY, CA
Homepage: https://www.mirumpharma.com
Description: Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.

Market cap and share counts drift.

Funds holding this security

184 funds · 185 positions · $1.39B reported value, as of 2026-03-31

All holders →

Fund	Ticker	Position value	% of fund	Balance	Match
VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS	VTI	$168.63M	0.01%	1,825,448 NS	FIGI
iShares Russell 2000 ETF iShares Trust	IWM	$95.01M	0.13%	1,028,481 NS	FIGI
State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR SERIES TRUST	XBI	$85.31M	1.15%	923,473 NS	FIGI
Janus Henderson Triton Fund JANUS INVESTMENT FUND	—	$71.96M	1.39%	778,947 NS	FIGI
SMALLCAP World Fund Inc SMALLCAP World Fund Inc	—	$66.92M	0.08%	724,415 NS	FIGI
Eventide Gilead Fund MUTUAL FUND SERIES TRUST	—	$65.51M	2.44%	709,135 NS	FIGI
Eventide Healthcare & Life Sciences Fund MUTUAL FUND SERIES TRUST	—	$63.82M	4.02%	690,846 NS	FIGI
Janus Henderson Global Life Sciences Fund JANUS INVESTMENT FUND	—	$63.32M	1.22%	685,482 NS	FIGI
VANGUARD SMALL-CAP INDEX FUND VANGUARD INDEX FUNDS	VB	$61.11M	0.04%	661,539 NS	FIGI
T. Rowe Price New Horizons Fund, Inc. T. ROWE PRICE NEW HORIZONS FUND, INC.	—	$49.24M	0.39%	533,020 NS	FIGI
VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS	VXF	$48.74M	0.06%	527,615 NS	FIGI
Janus Henderson Venture Fund JANUS INVESTMENT FUND	—	$41.90M	1.37%	453,555 NS	FIGI
iShares Biotechnology ETF iShares Trust	IBB	$36.28M	0.45%	392,677 NS	FIGI
Janus Henderson Research Fund JANUS INVESTMENT FUND	—	$35.43M	0.14%	383,566 NS	FIGI
VANGUARD SMALL-CAP GROWTH INDEX FUND VANGUARD INDEX FUNDS	VBK	$34.15M	0.09%	369,625 NS	FIGI

How positions resolve to the securities master. FIGI_COMPOSITE is exact identifier equality — both sides got the FIGI from Bloomberg. TICKER is a narrow fallback used only where the master row carries no FIGI at all (2,389 rows do not, disproportionately Irish-domiciled US listings like LIN and ACN). Roughly 22% of all positions resolve to the master.

Funds holding this security

Identifiers

master.security_identifier

TICKERMIRM
FIGI_COMPOSITEBBG00MH7T2M7
FIGI_SHARE_CLASSBBG00MH7T2N6
CIK0001759425
ISINUS6047491013
Resolved through OpenFIGI from a holdings ISIN, not supplied by the securities vendor.

Identifiers

Classification

classification.v_security_classification

Asset class: Equity
Sector: Health Care
Industry: Pharmaceuticals
Source: LLMunreviewed
Self-reported confidence: 0.95
Model: deepseek
Rationale: Mirum Pharmaceuticals is a biopharmaceutical company focused on rare diseases, classified under pharmaceutical preparations.

Classifications are unreviewed model output. All 5,771 assignments carry source = LLM and is_reviewed = false. Confidence is the model’s own estimate and is not calibrated — it clustered at 0.90–0.98 across the whole first pass, including rows that later proved wrong. Use it to order a review queue, not as a probability. Two share classes of one issuer can disagree.

Classification

Fund data

Not linked to a fund series.

Either this is not a fund, or it is one the SEC share-class snapshot cannot reach — commodity trusts and notes have no series ID at all.